Seladelpar 10 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 10 mg

Reference Brands: Livdelzi (USA/EU)

Category: Medical Aid

Seladelpar (Livdelzi) is used to treat Primary Biliary Cholangitis (PBC) in adults who did not respond adequately to or cannot tolerate Ursodeoxycholic acid (UDCA). It activates PPAR‑delta receptors to reduce bile acid production, inflammation, and liver fibrosis — helping improve liver function tests and relieve symptoms such as chronic itch (pruritus).

Product Description:

Seladelpar is a selective agonist at PPAR-delta, a nuclear receptor that regulates genes controlling bile acid synthesis and inflammation in the liver. Activating it suppresses the enzyme that makes bile acids from cholesterol, so the toxic bile acid load falls, while also damping hepatic inflammatory signalling. Primary biliary cholangitis destroys small bile ducts through an autoimmune process, and the resulting bile acid retention drives much of the ongoing injury.

It is used for primary biliary cholangitis in adults who have responded inadequately to ursodeoxycholic acid or cannot tolerate it — historically a group with few options. Alkaline phosphatase falls substantially on treatment, and, importantly to patients, so does pruritus, the relentless itch that dominates life with this disease and which some earlier treatments made worse. Headache, abdominal pain, nausea and transaminase elevation occur, and liver function requires monitoring.

Sourcing notes. Recently approved originator product, on patent, with accelerated approval in some markets pending confirmatory outcome data — registration and reimbursement status should be checked per destination. The patient population is small, predominantly middle-aged women, and treatment is lifelong, so demand is low-volume but durable. Oral capsules, room temperature.